

Robert M Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3910926/publications.pdf>

Version: 2024-02-01

154
papers

12,037
citations

36303

51
h-index

27406

106
g-index

155
all docs

155
docs citations

155
times ranked

11956
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Baseline Characteristics With Insulin Sensitivity and β -Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , 2021, 44, 340-349.	8.6	16
2	Association of glycemia with insulin sensitivity and β -cell function in adults with early type 2 diabetes on metformin alone. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107912.	2.3	5
3	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 537-547.	10.2	55
4	The cross-sectional association of cognition with diabetic peripheral and autonomic neuropathyâ€”The GRADE study. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108047.	2.3	3
5	Shape of the OGTT glucose response curve: relationship with β -cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002264.	2.8	12
6	Functional recreation of age-related CD8 T cells in young mice identifies drivers of aging- and human-specific tissue pathology. <i>Mechanisms of Ageing and Development</i> , 2020, 191, 111351.	4.6	6
7	Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108235.	2.8	20
8	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 682-690.	4.4	4
9	When HbA1c and Blood Glucose Do Not Match: How Much Is Determined by Race, by Genetics, by Differences in Mean Red Blood Cell Age?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 707-710.	3.6	27
10	The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 424-427.	2.2	11
11	Effect of vitamin D supplementation on cardiovascular risk in type 2 diabetes. <i>Clinical Nutrition</i> , 2019, 38, 2449-2453.	5.0	23
12	Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study. <i>Journal of the Endocrine Society</i> , 2018, 2, 310-321.	0.2	33
13	Hippocampal place cell dysfunction and the effects of muscarinic M ₁ receptor agonism in a rat model of Alzheimer's disease. <i>Hippocampus</i> , 2018, 28, 568-585.	1.9	13
14	The recovery index: A novel approach to measuring recovery and predicting remission in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 208, 369-374.	4.1	67
15	Low-level laser therapy for beta amyloid toxicity in rat hippocampus. <i>Neurobiology of Aging</i> , 2017, 49, 165-182.	3.1	111
16	Antibodies to biotinylated red blood cells in adults and infants: improved detection, partial characterization, and dependence on red blood cellâ€”biotin dose. <i>Transfusion</i> , 2017, 57, 1488-1496.	1.6	16
17	Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimerâ€™s disease. <i>Brain</i> , 2017, 140, 3023-3038.	7.6	146
18	Associations of Early Kidney Disease With Brain Magnetic Resonance Imaging and Cognitive Function in African Americans With Type 2 Diabetes Mellitus. <i>American Journal of Kidney Diseases</i> , 2017, 70, 627-637.	1.9	35

#	ARTICLE	IF	CITATIONS
19	Can Red Blood Cell Indices Act as Surrogate Markers for Discordance between Hemoglobin A1c and Fasting Blood Glucose?. <i>Clinical Chemistry</i> , 2016, 62, 1551-1553.	3.2	2
20	Do Red Blood Cell Indices Explain Racial Differences in the Relationship between Hemoglobin A1c and Blood Glucose?. <i>Journal of Pediatrics</i> , 2016, 176, 7-9.	1.8	6
21	Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia. <i>American Journal of Hematology</i> , 2016, 91, 1195-1201.	4.1	38
22	Patient-reported functioning in major depressive disorder. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 160-169.	2.5	45
23	Use of an oral stable isotope label to confirm variation in red blood cell mean age that influences HbA1c interpretation. <i>American Journal of Hematology</i> , 2015, 90, 50-55.	4.1	31
24	Physiologic Concepts That May Revise the Interpretation and Implications of HbA1C in Clinical Medicine. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 696-700.	2.2	6
25	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. <i>Kidney International</i> , 2015, 87, 649-659.	5.2	158
26	PATIENT-REPORTED OUTCOMES OF QUALITY OF LIFE, FUNCTIONING, AND DEPRESSIVE SYMPTOM SEVERITY IN MAJOR DEPRESSIVE DISORDER COMORBID WITH PANIC DISORDER BEFORE AND AFTER SSRI TREATMENT IN THE STAR*D TRIAL. <i>Depression and Anxiety</i> , 2014, 31, 707-716.	4.1	16
27	Are glycosylated serum proteins ready for prime time?. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 264-265.	11.4	18
28	Measurement of Posttransfusion Red Cell Survival With the Biotin Label. <i>Transfusion Medicine Reviews</i> , 2014, 28, 114-125.	2.0	43
29	Incorporating Multidimensional Patient-Reported Outcomes of Symptom Severity, Functioning, and Quality of Life in the Individual Burden of Illness Index for Depression to Measure Treatment Impact and Recovery in MDD. <i>JAMA Psychiatry</i> , 2013, 70, 343.	11.0	70
30	Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D). <i>Journal of Affective Disorders</i> , 2013, 151, 59-65.	4.1	54
31	Epidemiology and Clinical Diagnosis. <i>PET Clinics</i> , 2013, 8, 391-405.	3.0	5
32	Changes in the properties of normal human red blood cells during in vivo aging. <i>American Journal of Hematology</i> , 2013, 88, 44-51.	4.1	90
33	A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric A β , and Frank Neuronal Loss. <i>Journal of Neuroscience</i> , 2013, 33, 6245-6256.	3.6	376
34	Amyloid- β Positron Emission Tomography Imaging Probes: A Critical Review. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 613-631.	2.6	71
35	Sexual Satisfaction and Quality of Life in Major Depressive Disorder Before and After Treatment With Citalopram in the STAR*D Study. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 256-261.	2.2	31
36	Measurement Of Erythrocyte Survival In Vivo using a Stable Isotope Label In Sickle Cell Anemia. <i>Blood</i> , 2013, 122, 2223-2223.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Racial and Ethnic Differences in the Relationship between HbA1c and Blood Glucose: Implications for the Diagnosis of Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1067-1072.	3.6	221
38	Comparing Multiple Measures of Glycemia: How to Transition from Biomarker to Diagnostic Test?. <i>Clinical Chemistry</i> , 2012, 58, 1615-1617.	3.2	25
39	When the Blood Glucose and the HbA1c Don't Match: Turning Uncertainty Into Opportunity. <i>Diabetes Care</i> , 2012, 35, 2421-2423.	8.6	36
40	Hemoglobin A _{1c} : Teaching a New Dog Old Tricks. <i>Annals of Internal Medicine</i> , 2010, 152, 815.	3.9	29
41	Failing Compensatory Mechanisms During Working Memory in Older Apolipoprotein E- μ 4 Healthy Adults. <i>Brain Imaging and Behavior</i> , 2010, 4, 177-188.	2.1	29
42	Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial. <i>Diabetes Care</i> , 2010, 33, 983-990.	8.6	389
43	HbA1c for the Diagnosis of Diabetes and Prediabetes: Is It Time for a Mid-Course Correction?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5203-5206.	3.6	85
44	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <i>Lancet, The</i> , 2010, 376, 419-430.	13.7	1,182
45	Biologic Variability in Plasma Glucose, Hemoglobin A1c, and Advanced Glycation End Products Associated with Diabetes Complications. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 635-643.	2.2	46
46	Longitudinal Measurement of Ventricular Volume Gain in the Healthy Old. <i>Brain Imaging and Behavior</i> , 2009, 3, 370-378.	2.1	1
47	The Role of the Immune System in Alzheimer's Disease. <i>Focus (American Psychiatric Publishing)</i> , 2009, 7, 28-35.	0.8	3
48	A method for the continuous calculation of the age of labeled red blood cells. <i>American Journal of Hematology</i> , 2008, 83, 454-457.	4.1	23
49	Noninvasive Estimation of Normalized Distribution Volume: Application to the Muscarinic-2 Ligand [18F]FP-TZTP. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 420-430.	4.3	19
50	Discordant HbA1c Results: The Hoofbeats Increase. <i>Journal of Pediatrics</i> , 2008, 153, 7-9.	1.8	3
51	Evidence for Interindividual Heterogeneity in the Glucose Gradient Across the Human Red Blood Cell Membrane and Its Relationship to Hemoglobin Glycation. <i>Diabetes</i> , 2008, 57, 2445-2452.	0.6	109
52	Relationship of Prospective GHb to Glycated Serum Proteins in Incident Diabetic Retinopathy. <i>Diabetes Care</i> , 2008, 31, 151-153.	8.6	26
53	Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. <i>Blood</i> , 2008, 112, 4284-4291.	1.4	364
54	Frequency of HbA1c discordance in estimating blood glucose control. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2008, 11, 512-517.	2.5	50

#	ARTICLE	IF	CITATIONS
55	Pseudohypoglycemia: a Cause for Unreliable Finger-Stick Glucose Measurements. <i>Endocrine Practice</i> , 2008, 14, 337-339.	2.1	10
56	A1C: Does One Size Fit All?. <i>Diabetes Care</i> , 2007, 30, 2756-2758.	8.6	63
57	Glycemia Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S34-S43.	1.6	149
58	Hippocampal atrophy in the healthy is initially linear and independent of age. <i>Neurobiology of Aging</i> , 2006, 27, 1385-1394.	3.1	13
59	Functional magnetic resonance imaging and magnetoencephalography differences associated with APOE ϵ 4 in young healthy adults. <i>NeuroReport</i> , 2006, 17, 1585-1590.	1.2	49
60	Age and APOE ϵ 4 genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP. <i>Synapse</i> , 2006, 60, 86-92.	1.2	18
61	Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. <i>Annals of Neurology</i> , 2006, 59, 174-177.	5.3	85
62	Stability of CSF β -Amyloid ϵ 42 and Tau Levels by APOE Genotype in Alzheimer Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 48-53.	1.5	16
63	Biomarkers in the Diagnosis of Alzheimer's Disease: Are We Ready?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2006, 19, 172-179.	2.3	52
64	Evidence for Independent Heritability of the Glycation Gap (Glycosylation Gap) Fraction of HbA1c in Nondiabetic Twins. <i>Diabetes Care</i> , 2006, 29, 1739-1743.	8.6	120
65	A magnetoencephalography spatiotemporal analysis of neural activities during feature binding. <i>NeuroReport</i> , 2005, 16, 1747-1752.	1.2	6
66	Effects of Previous Major Depressive Illness on Cognition in Alzheimer Disease Patients. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 312-318.	1.2	14
67	Is Poor Glycemic Control Associated With Reduced Red Blood Cell Lifespan?. <i>Diabetes Care</i> , 2004, 27, 1013-1014.	8.6	16
68	Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 18171-18176.	7.1	334
69	Cerebrospinal fluid β -amyloid ϵ 42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE ϵ 4 allele. <i>Biological Psychiatry</i> , 2004, 56, 670-676.	1.3	168
70	Context-specific memory and apolipoprotein E (ApoE) [varepsilon]4: Cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2004, 10, 362-70.	1.8	47
71	In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. <i>Synapse</i> , 2003, 48, 39-44.	1.2	64
72	Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E ϵ 4 allele. <i>Synapse</i> , 2003, 49, 150-156.	1.2	59

#	ARTICLE	IF	CITATIONS
73	NAPLANAL: A Tool for Analyzing NAPL Saturation and Composition. <i>Ground Water</i> , 2003, 41, 298-299.	1.3	5
74	Decreased β -Amyloid ₁₋₄₂ and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2094-103.	7.4	579
75	Discordance Between HbA1c and Fructosamine: Evidence for a glycosylation gap and its relation to diabetic nephropathy. <i>Diabetes Care</i> , 2003, 26, 163-167.	8.6	191
76	Quantitative trait loci affecting the behavior of A/J and CBA/J intercross mice in the elevated plus maze. <i>Mammalian Genome</i> , 2001, 12, 501-507.	2.2	27
77	Opiate receptor avidity in the thalamus is sexually dimorphic in the elderly. <i>Synapse</i> , 2000, 38, 226-229.	1.2	13
78	Opiate receptor avidity is increased in rhesus monkeys following unilateral optic tract lesion combined with transections of corpus callosum and hippocampal and anterior commissures. <i>Brain Research</i> , 2000, 879, 1-6.	2.2	4
79	6-18F-DOPA PET study in patients with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2000, 100, 1-11.	1.8	92
80	Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. <i>Clinical Transplantation</i> , 1999, 13, 62-64.	1.6	11
81	The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Female Patients with Schizophrenia Evidence of a Sex Effect. <i>Neuropsychopharmacology</i> , 1999, 21, 632-640.	5.4	23
82	Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP. , 1999, 33, 282-288.		10
83	Physiologic and neuroendocrine responses to intravenous naloxone in subjects with Alzheimer's disease and age-matched controls. <i>Biological Psychiatry</i> , 1999, 46, 412-419.	1.3	16
84	Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys. <i>Brain Research</i> , 1998, 806, 292-296.	2.2	15
85	Abnormalities in the Distributed Network of Sustained Attention Predict Neuroleptic Treatment Response in Schizophrenia. <i>Neuropsychopharmacology</i> , 1998, 19, 36-47.	5.4	38
86	Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorder. <i>Biological Psychiatry</i> , 1998, 44, 998-1006.	1.3	78
87	Age-Related Changes in Brain Glucose Metabolism in Adults With Attention-Deficit/Hyperactivity Disorder and Control Subjects. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1998, 10, 168-177.	1.8	44
88	DOPA Decarboxylase Activity in Attention Deficit Hyperactivity Disorder Adults. A [Fluorine-18]Fluorodopa Positron Emission Tomographic Study. <i>Journal of Neuroscience</i> , 1998, 18, 5901-5907.	3.6	314
89	The Ratio of Mesial to Neocortical Temporal Lobe Blood Flow as a Predictor of Dementia. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 329-333.	2.6	11
90	Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 1997, 148, 171-180.	0.6	47

#	ARTICLE	IF	CITATIONS
91	Intravenous Dextroamphetamine and Brain Glucose Metabolism. <i>Neuropsychopharmacology</i> , 1997, 17, 391-401.	5.4	33
92	Abnormalities in sustained attention and anterior cingulate metabolism in subjects with resistance to thyroid hormone. <i>Brain Research</i> , 1996, 723, 23-28.	2.2	23
93	Presynaptic Dopaminergic Deficits in Leschâ€“Nyhan Disease. <i>New England Journal of Medicine</i> , 1996, 334, 1568-1572.	27.0	195
94	Regional brain glucose metabolism after acute α 2-blockade by idazoxan. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 684-695.	4.7	12
95	A Double FDG/PET Study of the Effects of Scopolamine in Older Adults. <i>Neuropsychopharmacology</i> , 1994, 10, 191-198.	5.4	26
96	Positron-Emission Tomography and Personality Disorders. <i>Neuropsychopharmacology</i> , 1994, 10, 21-28.	5.4	244
97	Right frontotemporal activation by tonal memory in dyslexia, an O15 PET study. <i>Biological Psychiatry</i> , 1994, 36, 171-180.	1.3	32
98	Gender-related differences in regional cerebral glucose metabolism in normal volunteers. <i>Psychiatry Research</i> , 1994, 51, 175-183.	3.3	124
99	Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [¹⁸ F]Cyclofoxy and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 24-42.	4.3	343
100	Reproducibility of Resting Cerebral Blood Flow Measurements with H ₂ ¹⁵ O Positron Emission Tomography in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 748-754.	4.3	75
101	Metabolic and cognitive changes in hereditary ataxia. <i>Journal of the Neurological Sciences</i> , 1993, 119, 134-140.	0.6	23
102	Effects of Acute Stimulant Medication on Cerebral Metabolism in Adults with Hyperactivity. <i>Neuropsychopharmacology</i> , 1993, 8, 377-386.	5.4	106
103	Positron emission tomography with 18F-DOPA: Interpretation and biological correlates in nonhuman primates. <i>Psychiatry Research - Neuroimaging</i> , 1992, 45, 153-168.	1.8	14
104	Plasma catecholamines and their metabolites in obsessive-compulsive disorder. <i>Psychiatry Research</i> , 1991, 37, 321-331.	3.3	30
105	Reduced cerebrospinal fluid dynorphin A1â€“8 in Alzheimer's disease. <i>Biological Psychiatry</i> , 1991, 30, 81-87.	1.3	16
106	Distribution and Kinetics of 3-O-Methyl-6-[18F]fluoro-L-DOPA in the Rhesus Monkey Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1991, 11, 726-734.	4.3	49
107	A review of immiscible fluids in the subsurface: Properties, models, characterization and remediation. <i>Journal of Contaminant Hydrology</i> , 1990, 6, 107-163.	3.3	614
108	TRH attenuates scopolamine-induced memory impairment in humans. <i>Psychopharmacology</i> , 1990, 100, 84-89.	3.1	79

#	ARTICLE	IF	CITATIONS
109	Cerebral Glucose Metabolism in Adults with Hyperactivity of Childhood Onset. <i>New England Journal of Medicine</i> , 1990, 323, 1361-1366.	27.0	881
110	Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. <i>Psychopharmacology</i> , 1989, 99, 129-133.	3.1	34
111	Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. <i>Psychopharmacology</i> , 1989, 98, 403-407.	3.1	71
112	In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM): A potential imaging ligand for D-2 dopamine receptors in spect. <i>Life Sciences</i> , 1988, 42, 2097-2104.	4.3	43
113	The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. <i>Life Sciences</i> , 1988, 43, 1141-1150.	4.3	48
114	High-Dose Naloxone in Older Normal Subjects: Implications for Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 1988, 36, 681-686.	2.6	9
115	Failure of High Dose Naloxone to Relieve Tardive Dyskinesia. <i>Journal of Clinical Psychopharmacology</i> , 1987, 7, 364.	1.4	1
116	Long-term imipramine treatment enhances locomotor and food intake suppressant effects of chlorophenylpiperazine in rats. <i>British Journal of Pharmacology</i> , 1987, 91, 747-752.	5.4	47
117	Glucose utilization in the temporal cortex of affectively ill patients: Positron emission tomography. <i>Biological Psychiatry</i> , 1987, 22, 545-553.	1.3	149
118	Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. <i>Life Sciences</i> , 1987, 40, 2031-2039.	4.3	132
119	Confidence Limits for Correlations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1987, 7, 820-820.	4.3	0
120	The effects of glutaraldehyde cross-linking on the function of the adenylate cyclase complex of turkey erythrocytes. <i>Life Sciences</i> , 1986, 38, 2151-2161.	4.3	2
121	Design and interpretation of opiate antagonist trials in dementia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1986, 10, 611-626.	4.8	9
122	Pharmacologic modelling of Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1986, 10, 599-610.	4.8	101
123	Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl. <i>Psychiatry Research</i> , 1986, 17, 119-127.	3.3	49
124	Foot shock induces time and region specific adrenergic receptor changes in rat brain. <i>Pharmacology Biochemistry and Behavior</i> , 1986, 24, 1587-1592.	2.9	21
125	Naloxone Reduces Food Intake in Humans. <i>Psychosomatic Medicine</i> , 1985, 47, 132-138.	2.0	47
126	Tyramine pressor sensitivity changes during deprenyl treatment. <i>Psychopharmacology</i> , 1985, 86, 432-437.	3.1	83

#	ARTICLE	IF	CITATIONS
127	Scopolamine challenges in Alzheimer's disease. <i>Psychopharmacology</i> , 1985, 87, 247-249.	3.1	65
128	Positron Emission Tomography in Schizophrenic Patients with and without Neuroleptic Medication. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1985, 5, 201-206.	4.3	175
129	6-Hydroxydopamine pretreatment effects on α - and β -adrenergic receptor adaptation to clorgyline. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1985, 329, 158-161.	3.0	6
130	Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat. <i>Pharmacology Biochemistry and Behavior</i> , 1985, 23, 921-925.	2.9	14
131	How memory fails: A theoretical model. <i>Geriatric Nursing</i> , 1985, 6, 144-148.	1.9	6
132	Glutaraldehyde pretreatment blocks phospholipase A2 modulation of adrenergic receptors. <i>Life Sciences</i> , 1985, 36, 25-32.	4.3	11
133	TRH stimulation test in dementia of the Alzheimer type and elderly controls. <i>Psychiatry Research</i> , 1985, 16, 269-275.	3.3	39
134	Hormonal effects of high dose naloxone in humans. <i>Neuropeptides</i> , 1985, 6, 373-380.	2.2	23
135	Antidepressants in states of cognitive dysfunction. <i>Drug Development Research</i> , 1984, 4, 517-532.	2.9	5
136	Endocrine effects of the cold pressor test: Relationships to subjective pain appraisal and coping. <i>Psychiatry Research</i> , 1984, 12, 227-233.	3.3	50
137	High-dose naloxone affects task performance in normal subjects. <i>Psychiatry Research</i> , 1983, 8, 127-136.	3.3	49
138	The dynamics of neurotransmitter regulation and antidepressant efficacy. <i>Behavioral and Brain Sciences</i> , 1983, 6, 551.	0.7	0
139	Correlated cholinomimetic-stimulated beta-endorphin and prolactin release in humans. <i>Peptides</i> , 1982, 3, 319-322.	2.4	20
140	The dexamethasone suppression test in patients with primary obsessive-compulsive disorder. <i>Psychiatry Research</i> , 1982, 6, 153-160.	3.3	125
141	Physiological effects of high dose naloxone administration to normal adults. <i>Life Sciences</i> , 1982, 30, 2025-2031.	4.3	59
142	CLINICAL AND EXPERIMENTAL STUDIES OF STRESS AND THE ENDOGENOUS OPIOID SYSTEM. <i>Annals of the New York Academy of Sciences</i> , 1982, 398, 424-432.	3.8	6
143	Lifetime monoamine oxidase inhibition and sleep. <i>Pharmacology Biochemistry and Behavior</i> , 1982, 16, 429-431.	2.9	15
144	REM sleep suppression induced by selective monoamine oxidase inhibitors. <i>Psychopharmacology</i> , 1982, 78, 137-140.	3.1	58

#	ARTICLE	IF	CITATIONS
145	Episodic secretion of opioid activity in human plasma and monkey CSF: Evidence for a diurnal rhythm. Life Sciences, 1981, 28, 931-935.	4.3	60
146	Physostigmine induction of depressive symptomatology in normal human subjects. Psychiatry Research, 1981, 4, 89-94.	3.3	100
147	The Dexamethasone Suppression Test as a Measure of Hypothalamic-Pituitary Feedback Sensitivity and its Relationship to Behavioral Arousal. Neuroendocrinology, 1981, 32, 92-95.	2.5	44
148	Peptide Challenges in Affective Illness. Journal of Clinical Psychopharmacology, 1981, 1, 214-222.	1.4	5
149	Tyramine infusions and selective monoamine oxidase inhibitor treatment. Psychopharmacology, 1981, 74, 8-12.	3.1	30
150	Assessing pharmacologically induced dopamine receptor sensitivity changes with the ungerstedt turning model. Psychopharmacology, 1981, 75, 212-213.	3.1	5
151	Naloxone effects on β -endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers. Psychopharmacology, 1981, 74, 125-128.	3.1	87
152	Diurnal Variation in Cerebrospinal Fluid Prolactin Concentration of the Rhesus Monkey. Journal of Clinical Endocrinology and Metabolism, 1981, 52, 857-858.	3.6	11
153	Circadian variation in the CSF cortisol concentration of the rhesus monkey. Life Sciences, 1980, 26, 1485-1487.	4.3	7
154	Presynaptic noradrenergic regulation during depression and antidepressant drug treatment. Psychiatry Research, 1980, 3, 93-105.	3.3	91